Background: Multiple endocrine neoplasia type 1 (MEN1) is associated with significant morbidity and mortality. Timely detection of MEN1 kindred, together with treatment of associated tumours, results in an improved outcome. We describe how the development of a dedicated multidisciplinary MEN clinic has improved the diagnosis and treatment of MEN1-associated endocrinopathies. Design and patients: A dedicated MEN clinic was developed at Aintree University Hospital, Liverpool in 2002 for patients living in Merseyside, Cheshire and North Wales. The multidisciplinary approach adopted, aimed to improve communication and continuity of care. Patients see all clinicians involved in their care (Consultant Endocrinologist, Paediatrician, Clinical Geneticist and Endocrine Surgeon) simultaneously, allowing for a unified, clear approach and a reduction in unnecessary attendances. The clinicians adopt a proactive approach to tracing the relatives of patients, with
Introduction
The term 'multiple endocrine neoplasia' (MEN) was first adopted by Steiner in 1968 to describe disorders featuring combinations of endocrine tumours. 1 The first case of an acromegalic patient with a pituitary adenoma and three enlarged parathyroid glands was described by Erdheim in 1903, and 50 years later the first case series of eight patients with pituitary, parathyroid and pancreatic islet adenomas was reported. 2 Wermer discovered that the syndrome of pituitary, parathyroid and pancreatic islet tumours was transmitted in an autosomal dominant manner 3 and it was the 'Wermer syndrome' that was designated MEN type 1 (MEN1) in later years. 1 It is now recognized that neuroendocrine tumours may also occur at sites such as the duodenum, thymus and adrenal gland in MEN1 and that in addition there is a higher prevalence of carcinoid tumours in patients with MEN1 than the general population.
Linkage to chromosome 11q13 was first demonstrated in MEN1 families in 1988 by Larsson. 4 Subsequent research over the following decade identified the critical region, culminating in the cloning of the MEN1 gene in 1997. 5 The MEN1 gene encodes a 610 amino acid protein called menin. 5, 6 A recent analysis of reported MEN1 mutations showed that some mutations recur in unrelated kindreds, with 20% of a total of 1133 independent germline mutations accounted for by nine mutations, suggesting there may be 'potential mutation hot spots' in the MEN1 gene. 7 However, mutations in MEN1 have been observed throughout the entire coding region with deletion, insertion, nonsense, missense, frameshift and slice site mutations all having been reported. 7 Currently, gene mutations can be identified in up to 90% of familial MEN1 cases. 8 Little evidence exists for a genotype-phenotype correlation in MEN1 unlike in MEN2. 9 Since the first descriptions of MEN and subsequent identification of germline mutations, there has been increased awareness of the variable clinical presentations of MEN, together with a large number of case reports published in the literature. The first consensus statement regarding management of patients with MEN was published in the Journal of Clinical Endocrinology and Metabolism in 2001, 10 and highlighted the importance of a systemic, evidence-based approach to the management of patients with MEN. The guidelines proposed by the MEN consensus statement were aimed at improving diagnosis and management of patients with MEN. In line with international practice, a dedicated multidisciplinary clinic was formed at Aintree University Hospital, Liverpool in 2002, with the intention of providing a specialized multidisciplinary service to patients with MEN from Merseyside, Cheshire and North Wales (population 3.5 million). Whilst the service was established to manage patients with both MEN1 and MEN2, at present only patients with MEN1 are under the service. This is due to the much lower prevalence of MEN2 than MEN1.
In the rest of this article, we describe the outcomes of establishing a dedicated MEN clinic in terms of increased diagnosis of patients with MEN1 gene mutation, increased recognition of MEN1-related endocrinopathy and increased need for surgical treatment. We also consider the potential impact on service provision of the increased diagnosis in MEN1-associated endocrinopathy that has occurred following the adoption of MEN consensus statement guidelines. We also highlight examples of practices established and difficulties overcome within our dedicated MEN clinic, which support the need for a specialized multidisciplinary approach to the management of MEN1.
Patients and methods: the establishment of the Aintree MEN clinic
The MEN clinic at Aintree University Hospital was established in 2002, with the aim of providing comprehensive, effective, expert, integrated, multidisciplinary care to patients with MEN. The clinical team currently consists of two endocrinologists, an endocrine surgeon, a paediatric endocrinologist and a clinical geneticist. There is also frequent communication and collaboration from colleagues in gastroenterology, hepatobiliary surgery, radiology and nuclear medicine. Cases with pancreatic neuroendocrine tumours are also discussed at a designated bimonthly regional neuroendocrine tumour multidisciplinary team meeting with gastroenterologists and pancreatic surgeons. The service is consultant delivered and all clinicians are present together in the same room during each consultation. This enables a clear discussion of an individual detailed management plan with each patient, resulting in a unified approach, and thereby preventing miscommunication with the patient and between disciplines that may otherwise occur as a consequence of multiple individual consultations. In addition, the clinical geneticist provides detailed genetic counselling to the patients and arranges for tracing and contact of family members where appropriate. Usually this requires an additional meeting between the patient, family members and the geneticist. The presence of a surgeon at each consultation is important to ensure all surgery for endocrinopathies is planned appropriately and at a time that is fitting to the holistic management of the patient. The role of the paediatrician is to discuss optimal timing for genetic screening in any children of affected kindreds and also to provide detailed insight into differences in paediatric and adult management of the condition. The presence of the paediatric and adult endocrinologists at the same clinic also facilitates smooth transition of care from childhood to adulthood at a time that is appropriate to the patient's clinical, emotional and social needs.
The clinic at Aintree currently runs every 3 months. Asymptomatic patients known to have a genetic mutation for MEN1 are seen on an annual basis for the organization and review of biochemical and radiological investigations that are performed for the surveillance of MEN1-associated tumours. Patients with known MEN1-associated pathology are seen as often as is required to allow the planning of further management.
Results
When the Aintree MEN clinic was initially established in 2002 there were a total of 16 patients with suspected or confirmed MEN1, from five different families who had previously been attending a combination of general surgical, general endocrine and gastroenterology clinics around the region. Of these 16 patients, only 1 had already undergone confirmatory genetic testing, 9 patients were thought to have probable MEN1 and another 6 were thought to have possible MEN1 based on clinical presentation. Formal family tracing and screening had not been performed in any of the kindred under follow up. The 16 patients originally attending the MEN clinic had in total 20 MEN1-associated tumours that had been previously diagnosed and treated. The endocrinopathies comprised 12 cases of hyperparathyroidism, 3 pituitary tumours (all macroprolactinomas), 4 pancreatic/upper GI neuroendocrine tumours (3 gastrinomas, 1 insulinoma) and 1 adrenal cortical adenoma. Through the accomplishment of the clinic's primary goals, including identification and genetic screening of patients at risk of having MEN1, together with surveillance of patients known to have MEN1, the Aintree MEN clinic has rapidly expanded and 6 years after its establishment, has managed 45 MEN1 patients from 15 families with a total of 83 neuroendocrine tumours. The endocrinopathies diagnosed to date are described in Table 1 .
In total, 62 patients have received genetic counselling and screening since the establishment of the Aintree MEN clinic, compared with just 1 patient prior to the clinic's establishment. A MEN1 mutation has been confirmed in 11 of the 15 families, accounting for 41 of the patients attending the clinic ( Table 2) . Two of the families attending the clinic have the same mutation but are apparently unrelated. Genetic analysis has failed to find any mutation of the MEN1 gene in the remaining four patients, who are from unrelated families. These patients have also had DNA sent for p27kip1 (CDKN1B). The clinical picture and the family history of these four patients is such that MEN1 is thought to be a likely diagnosis based on previously published criteria for diagnosis, 10 and therefore these patients are managed in an identical manner to those who have been found to have an MEN1 gene mutation. Twelve of the MEN1 mutations found in patients attending the Aintree MEN service have not previously been reported. Those mutations that have been described previously were reported as novel mutations by colleagues from the Peninsula Clinical Genetics service 8 and therefore represent our patients (Families 1, 5 and 6) as it is the Peninsula service which receives the blood samples of the Aintree MEN patients for genetic analysis. None of the MEN1 gene mutations found in the Aintree population fell into any of the 'potential mutation hot spots' on the MEN1 gene recently reported by Lemos et al. 7 Of the 45 patients managed by the clinic, 28 were known to have endocrinopathies prior to the diagnosis of MEN1 being established. Sixteen of these 28 patients were diagnosed with MEN1 as a direct consequence of presenting with their endocrinopathies, whereas the remaining 12 patients were diagnosed only after MEN1 had been confirmed in a family member attending the Aintree clinic, despite many of them already having diagnostic features of MEN1 themselves. Seventeen patients currently attending clinic who were diagnosed with MEN1 after MEN1 had been diagnosed in a family member had not presented with any endocrinopathy prior to being diagnosed with MEN1. Subsequent investigation and follow-up of these patients has resulted in a diagnosis of a total of 23 endocrinopathies in 14 of the patients. In addition important morbidities related to hyperparathyroidism, such as renal stone disease, osteoporosis and hypertension, have been diagnosed in 50% of these previously asymptomatic patients. The mean number of endocrinopathies was higher in those patients diagnosed with MEN1 clinically compared with those diagnosed through genetic screening (2.1 vs. 1.6, P = 0.12). Although this difference failed to reach statistical significance, the trend for the presence of a higher number of endocrinopathies in clinically diagnosed as opposed to genetically diagnosed patients is in keeping with a study recently published by Pieterman et al. 11 However, despite the lower prevalence of endocrinopathy in those patients diagnosed with MEN1 through genetic screening there is a role for early genetic testing in patients at risk of MEN1 as it allows earlier diagnosis of conditions such as hyperparathyroidism which although may be clinically silent initially, may be associated with long-term complications such as osteoporosis, chronic kidney disease and hypertension. Therefore early genetic testing of patients at risk of MEN1 is important in improving long-term outcomes. Pituitary apoplexy, characterized by sudden onset of headache, meningism and cranial nerve defects, was the presenting feature in two unrelated patients who now attend the Aintree MEN clinic. Both patients underwent pituitary surgery and made a good recovery. Prolactin concentration in both patients was normal postoperatively. Both were found to have hyperparathyroidism and both had confirmatory genetic tests leading to a diagnosis of MEN1 [frameshift mutation of exon 7 (c.1089delT) and missense mutation of exon 4 (c.831T > C)].
Surgical procedures
The early and comprehensive detection of endocrinopathies that has been facilitated by the specialized and systematic approach of the clinic has necessitated the provision of an increase in the number of surgical procedures performed. Since the clinic was established, 7 pancreatic procedures and 19 parathyroidectomies for new or recurrent disease have been performed in 23 patients compared with 5 pancreatic procedures and 16 parathyroidectectomies performed in 9 patients prior to the clinic being established. With a further 9 patients currently considering parathyroidectomy and 7 patients under observation for known or suspected pancreatic disease, it is expected that the increased requirement for surgical intervention will continue and needs to be accounted for in future plans for service provision. The details of surgical interventions performed to date are listed in Table 3 .
Future genetic testing
Since the establishment of the Aintree MEN clinic, the number of patients requiring specialized care and follow-up has increased by 300% (from 16 to 45), with the number of endocrinopathies managed, experiencing an increase of 400% (from 24 to 97). This growth is likely to continue as the tracing of further family members is still in progress and continues to reveal an exponential number of relatives who require screening for MEN1. This not only has cost implications in terms of genetic testing but also in the time required for review and counselling in the MEN clinic. To date, 62 patients have attended for genetic screening for MEN1 and the up take for genetic testing has, so far, been 100%. Seventeen relatives of patients known to have MEN1 have attended the clinic with a subsequent result of a negative genetic test. A further 94 known relatives have yet to receive genetic counselling and screening. There are a number of reasons for this. First, some relatives live outside the catchment area of the clinic and therefore results of genetic tests are not sent directly to us. We rely on the index case to inform us of the outcome of their relative's genetic tests but they are not always aware of the results or even if the test has been carried out. Second, a proportion of relatives awaiting genetic screening are children and it is not unusual for their parents to opt to defer screening for a few years. Third, the establishment of the clinic has resulted in the generation of a large number of referrals to the geneticist for counselling. The counselling procedure for genetic screening of healthy individuals is lengthy and a proportion of relatives awaiting screening are on a waiting list to be seen by the geneticist.
Of the 94 relatives awaiting genetic screening, 48 are first degree relatives and so are at a 50% risk of having MEN1 gene mutations, 40 are second degree relatives putting them at a 25% risk and 6 are third degree relatives giving them at 12.5% risk. From this data, it can be extrapolated that approximately 35 of the 94 known relatives would be expected to have a MEN1 mutation, requiring an 80% increase (from 45 to 80 patients) in the current capacity of clinic, as well as an increase in the number of investigations performed and surgical procedures needed to manage these patients appropriately. These calculations do not account for new families who may present to the service. Although a negative genetic screen in some of the first or second degree relatives would obviate the need to test a proportion of the second and third degree relatives respectively, it is likely that the number of index case relatives at risk of MEN1 is underestimated as many of the family trees remain incomplete.
Discussion
The frequency of detection and the type of endocrinopathies diagnosed in the patients attending the Aintree clinic very closely reflect that described in other centres. 10 However, the diagnosis of pituitary apoplexy in two patients attending the clinic is an exception to this. Pituitary apoplexy is the presenting feature in 5% of all pituitary macroadenomas 12 and has not previously been reported in association with MEN1. Therefore, the high prevalence of pituitary apoplexy in the Aintree MEN clinic is most unusual and may reflect chance and the slightly higher ratio of macro-to micro-adenomas in the Aintree MEN population compared to that reported in other MEN1 populations. 10, 13 Different tumour characteristics which are dependent on genetic predisposition are also known to predispose to apoplexy and therefore the type of MEN1 mutation in these two patients may also play an important role. 14 The Aintree MEN clinic is undergoing continuous development to reflect the needs of the patients that attend. The primary aims to assess possible cases, review family histories, offer genetic counselling and testing, and the establishment of a programme of annual endocrine surveillance for patients with MEN1 have all been fulfilled. Achievement of these goals has made a significant impact on the continuity of care and holistic management of the patients attending the clinic as has been demonstrated by the examples above. In particular, there are several examples where prompt diagnosis and detection of disease has facilitated earlier and more efficacious treatment, thereby significantly reducing future morbidity occurring from hormone excess or malignancy. This includes the detection of asymptomatic hyperparathyroidism in a number of patients.
Accurate completion of family trees in known cases of MEN can be challenging for many reasons, particularly when the index case is identified later in life when older generations who are often the source of family history are no longer alive. In addition, patients sometimes do not have up to date contact details of their relatives, particularly if their relatives have moved out of the area or emigrated abroad. Pre-existing conflict within families may also provide a hurdle to tracing potential patients with MEN. Also family conflict may result in problems if patients are brought to the same clinic. We have not experienced this within our clinic to date but if family conflict does become a real issue, arrangements can be made to bring family members to different clinics as not all patients are seen at every clinic. Many patients are under annual review for screening purposes so it is feasible to avoid bringing members of the same family to clinic if necessary. Medical confidentiality within a family is always maintained within the clinic as diagnoses and management of individual patients are not discussed with other family members without the expressed wish of the individual.
The input of an experienced clinical geneticist is vital to the process. Large families present a unique challenge to the MEN clinic as the family tree is often complex and a large amount of time is required to trace, contact and counsel family members. The largest family attending the Aintree clinic is currently known to have 63 living members but at present the family tree is incomplete (Figure 1 ). The index case is a 22-year-old lady who presented in 2001 with a prolactinoma and a strong family history of hyperparathyroidism. This history initiated further investigations that revealed the index case to also have hyperparathyroidism, with genetic analysis revealing a deletion in exon 7 (c.1089delT) of the MEN1 gene. The index patient's father has 12 siblings of which 11 are still alive. To date, six of them have been diagnosed with MEN1 and tracing of their children is now ongoing. Four of the index case's father's siblings were found to have hyperparathyroidiam and two are under investigation for possible gastrinomas. Unfortunately a paternal aunt of the index case presented with pituitary apoplexy whilst she was in the process of being screened.
We are aware that there are some patients with MEN1 who live within the region but who have not been referred to the dedicated multidisciplinary clinic. They currently attend general medical, endocrine or gastroenterology clinics in other hospitals. The general consensus is that patients with MEN should attend a multidisciplinary clinic as this facilitates more timely diagnosis and management of endocrinopathies as well as enabling family tracing. 10 Attempts to disseminate information regarding the value to patient outcome of the multidisciplinary MEN clinic has been made through education sessions but despite that we know there are patients who are still seen in other clinics. This problem has been reported by clinicians from other dedicated MEN clinics and may be due to a protectionist attitude of some clinicians who wish to continue following up patients they perceive as being more interesting/rare cases.
Other challenges also remain in the management of patients with MEN1. These include tracing family members who have moved out of the area or have emigrated, or those who are no longer in contact with the index case. Geographical boundaries may also result in difficulties when trying to obtain accurate information regarding a suspected index patient's past or family medical history. Patients that are suspected of having MEN1 on clinical grounds but do not have any of the known genetic mutations in the MEN1 genes also present difficulties as there is no current evidence to help determine how they should be followed up or with what frequency their relatives should be investigated. In addition, encouraging asymptomatic MEN1 patients or people who are at risk of having MEN1 to attend hospital and undergo investigations regularly can sometimes be difficult, but with the correct information and timely counselling given at the appropriate level, this problem is usually overcome.
The success of the clinic, as shown by the exponential increase in detection of patients at risk of MEN1, the number of endocrinopathies diagnosed and the number of surgical procedures performed since the establishment of the clinic, is predominantly a consequence of the multidisciplinary, integrated, systematic, comprehensive and evidence-based approach that is delivered by senior experienced clinicians. It is important that this structure is maintained if patients with MEN1 are to continue to receive appropriate and timely care. Patients with MEN1 require complex care and evidence supports patients are best managed by specialized teams in tertiary centres with key members rather than on a case by case basis with inconsistent access of facilities and expertise. 8 The main challenge to the model, however, is the ever increasing numbers of patients who require screening, surveillance and treatment, and this has implications in the planning of service provision in the future. Patients with identified endocrinopathy do need to attend the MEN clinic regularly so that surgery can be planned. Patients with a MEN1 gene mutation but without active disease only need to be seen once a year in clinic to ensure all blood and radiology investigations are organized and to review the patients for the development of new symptoms. Results of the investigations are then communicated to the patient either by letter or through the primary care physician rather than bringing them back to clinic. If further routine investigations are required as a consequence of results of annual screening investigations, then these are organized in primary care. If annual screening results suggest more complex investigations are required the patients are brought back to clinic to discuss these in more detail.
There are important arguments against the suggestion that follow-up of those patients who have treated endocrinopathy or no identified endocrinopathy to date, be devolved to primary care in an attempt to ease the burden on the clinic. First, primary care physicians are not trained to interpret the results of certain tests such as those of pituitary function or gut hormones and may not be aware of certain requirements for testing such as which bottles to use, the need to discontinue proton pump inhibitors and fasting requirements. This may lead to misinterpretation of results by both the primary care physician as well as the MEN team if they are not aware of the circumstances in which the tests are performed. Secondly, there is reluctance in primary care to take responsibility for organizing screening tests for a condition that is rare and of which the physicians have no experience of managing. Whilst there may be a role for an Endocrine Specialist Nurse in the management of MEN patients, this would not negate the need for the patients to be reviewed annually by the clinicians in the multidisciplinary team.
Early genetic screening is paramount to reduce long-term complications associated with MEN1 11 and with effective genetic screening it can be expected that the number of patients attending clinic, the number of investigations required and the number of surgical procedures performed will continue to increase exponentially. Individual patient tumour penetrance cannot be predicted and therefore life-long follow-up of known MEN1 carriers is essential. 15 The Aintree MEN clinic has a catchment population of 3.5 million people. Given that the prevalence of MEN1 is estimated to be around 3-5 per 100 000 population, 16 it can be expected that the number of patients requiring follow-up and treatment will increase by a further 300-400% over coming years, with up to 180 patients requiring follow-up and treatment. At present, the clinic runs every 3 months with 15 patients reviewed at each clinic. Whilst this service provision is currently adequate, if the expected exponential rise in patients requiring follow-up is realized, it will be necessary for the service to undergo significant development to meet the provisions required which in the current economic environment may prove to be a significant challenge.
